Vanguard Group Inc. Has $24.41 Million Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Vanguard Group Inc. boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 8.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,843,740 shares of the biotechnology company's stock after acquiring an additional 143,584 shares during the period. Vanguard Group Inc. owned approximately 6.06% of AnaptysBio worth $24,411,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ANAB. KLP Kapitalforvaltning AS acquired a new position in AnaptysBio in the 4th quarter worth $40,000. AlphaQuest LLC boosted its position in shares of AnaptysBio by 1,891.5% during the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock worth $59,000 after buying an additional 4,237 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of AnaptysBio by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock worth $85,000 after buying an additional 644 shares during the period. SG Americas Securities LLC grew its holdings in shares of AnaptysBio by 35.0% during the fourth quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company's stock worth $216,000 after buying an additional 4,231 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in AnaptysBio in the 4th quarter valued at approximately $311,000.

AnaptysBio Trading Up 7.8 %

NASDAQ:ANAB traded up $1.49 on Friday, hitting $20.55. The company's stock had a trading volume of 599,640 shares, compared to its average volume of 593,425. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $41.31. The stock has a fifty day moving average of $17.80 and a two-hundred day moving average of $19.86. The firm has a market capitalization of $630.21 million, a P/E ratio of -3.38 and a beta of -0.09.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.61) by $0.89. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $43.11 million during the quarter, compared to the consensus estimate of $10.17 million. As a group, sell-side analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its board has authorized a stock buyback plan on Monday, March 24th that authorizes the company to repurchase $75.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to repurchase up to 13.1% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ANAB. Wells Fargo & Company raised their price target on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. HC Wainwright reiterated a "neutral" rating and issued a $22.00 price target on shares of AnaptysBio in a research note on Tuesday, March 4th. JPMorgan Chase & Co. boosted their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Wedbush restated an "outperform" rating and issued a $40.00 price objective on shares of AnaptysBio in a report on Wednesday, February 12th. Finally, Johnson Rice reiterated a "buy" rating on shares of AnaptysBio in a report on Wednesday, March 26th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $33.63.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.